CN106962910A - A kind of health composition of hypotensive - Google Patents
A kind of health composition of hypotensive Download PDFInfo
- Publication number
- CN106962910A CN106962910A CN201710170853.3A CN201710170853A CN106962910A CN 106962910 A CN106962910 A CN 106962910A CN 201710170853 A CN201710170853 A CN 201710170853A CN 106962910 A CN106962910 A CN 106962910A
- Authority
- CN
- China
- Prior art keywords
- hawthorn
- mulberry leaf
- composition
- hypotensive
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 208000001953 Hypotension Diseases 0.000 title claims abstract description 16
- 208000021822 hypotensive Diseases 0.000 title claims abstract description 16
- 230000001077 hypotensive effect Effects 0.000 title claims abstract description 16
- 230000036541 health Effects 0.000 title claims abstract description 14
- 241001092040 Crataegus Species 0.000 claims abstract description 33
- 240000000249 Morus alba Species 0.000 claims abstract description 33
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 33
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 32
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 32
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 32
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 32
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 32
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 32
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 32
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 32
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 32
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 26
- 239000001387 apium graveolens Substances 0.000 claims abstract description 24
- 240000007087 Apium graveolens Species 0.000 claims abstract description 8
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims abstract description 8
- 235000010591 Appio Nutrition 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 abstract description 30
- 230000004531 blood pressure lowering effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 235000009508 confectionery Nutrition 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 235000019658 bitter taste Nutrition 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 29
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 28
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 18
- 206010020772 Hypertension Diseases 0.000 description 15
- 239000000284 extract Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000006286 aqueous extract Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000014493 Crataegus Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000001556 apium graveolens l. seed extract Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940116732 celery seed extract Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of health composition of hypotensive, said composition is that 50~70% mulberry leaf powders, 10~40% celery seeds and 4~20% hawthorn constitute by mass fraction；By the combination of these three materials, the deficiency of homogenous material presence can be eliminated, adverse reaction is reduced, such as hawthorn has neutralized the bitterness that is cold, alleviating celery seed of mulberry leaf, and hawthorn is sour sweet, and compatibility can adjust mouthfeel.Effect of mulberry leaf and celery seed causes blood pressure lowering effect more to protrude, and the blood pressure lowering effect after three kinds of material compatibilities is more preferable than the blood pressure lowering effect of homogenous material.
Description
Technical field
The present invention relates to blood pressure reducing composition preparing technical field, more particularly, to a kind of health-care combination of hypotensive
Thing.
Background technology
Vascular hypertension（HPyeertnsino）It is that harm the elderly is healthy " the first killer ", it is a kind of to be slowly in progress
Systemic chronic vascular lesion, is most common angiocardiopathy, and risk factors of patients with hypertension is sufficiently complex, except biology something lost
Pass, also have with the several factors such as production, living environment, social economy and health care outside the factor such as individual lifestyle or behavior
Close.China is in recent years due to the life of people, and acute infectious disease is controlled, and life is improved, and causes cardiovascular and cerebrovascular diseases
Patient increases, especially Hypertension incidence increase.Adult is pointed out in China's Third National hypertension census final report
The illness rate of hypertension is up to 11.88%, and blood pressure is generally in obvious ascendant trend, calculates that the existing hyperpietic of China has surpassed
Cross 100,000,000 people.Wherein light-duty hypertension number rising is more, is the key population of preventing and treating.
Most hyperpietics can only control after medicine Treatment of Hypertension is received and be difficult to cure, and easily produce
The resistance to the action of a drug, it means that hyperpietic needs to adhere to for a long time even life-long therapy, the medicine for treating hypertension is more, but much
Medicine has a certain degree of side effect.Modern hyperpietic is more concerned with medicine food combined treatment method, does not suffer from hypertension
The elderly also gradually appreciate care food for reducing blood pressure control blood pressure rise in terms of importance.Therefore, find and
The pure natural health-care antihypertensive product of exploitation Small side effects has become the development trend of this area research and development.
The requirement done harm to according to Pure natural nontoxic, is picked out from edible plant with blood pressure reduction effect, bioactivity
Composition is abundant, it is common known to be used as raw material.Mulberry leaf（Mulberry Leaf）It is bitter, sweet for the leaf of moraceae plants mulberry tree,
Can dispelling wind and heat from the body, clear liver and improve vision, clearing away the lungheat and moisturizing, a kind of Chinese herbal medicine included by NF.Chief active thing in mulberry leaf
Matter includes flavonoids, polysaccharide, polyphenol, alkaloid and amino acid etc., with hypoglycemic, reducing blood lipid, the anti-ageing effect of waiting for a long time.Grind recently
Study carefully in discovery, mulberry leaf containing abundant γ-aminobutyric acid（γ-aminobutyric acid, abbreviation GABA）, with reduction blood
The effect of pressure and reduction heart rate.
Celery seed is the seed of celery, is mainly used in treatment hypertension, arthritis, rheumatoid arthrosis in Uygur medicine
The disease such as inflammation, stagnation of the circulation of vital energy temper cervicitis, ascites, kidney, takes play hypotensive in short term, the effect of reducing blood lipid, and long-term taking is much
It is without any side effects better than other Pharmaceuticals.Celery seed has special efficacy to hypertension.
Hawthorn is rose family May（Crataegus L）Plant, fall leaves dilute semi-evergreen shrubs or dungarunga, the whole world is about
Kind more than 250.The acid temperature of haw taste, qi and blood is simultaneously walked, and stagnation resolvation is without hindering new blood, and row stagnant gas is without hindering healthy tendency, applied to meat stagnation
Disease, diarrhea dysentery abdominal pain, hernia pain, stasis of blood pectoralgia, lochiorrhagia, dysmenorrhoea, spits blood, has blood in stool.Modern alone this product preparation is controlled
Angiocardiopathy, bacillary dysentery etc. are treated, there is good therapeutic effect.Hawthorn has expansion peripheral vascular and made with lasting decompression
With.British scholar Walker researchs leaves of Hawthorn, flower, fruit extract solution treatment hypertensive diabetes, as a result show, take hawthorn and carry
The patient of liquid is taken to be decreased obviously compared with placebo diastolic pressure.Hawthorn syrup（Equivalent to crude drug in whole 0.7g/mL）, take 3 day, every time
20 mL, 1 month are 1 course for the treatment of, for hypertensive patient, and effective percentage can increase appetite up to 80%, improve sleep.Hawthorn is total
Extract also has more obvious central antihypertensive effect to mouse, rabbit, cat.
Above-mentioned three kinds of materials not only have good blood pressure lowering effect, also rich in Flavonoid substances, can improve blood and follow
Ring, effectively reduces the cardiovascular and cerebrovascular disease caused by hypertension symptom.But mulberry leaf cold nature, it is edible excessively to influence spleen
Stomach；Hawthorn slightly warm in nature, sour sweet, stomach strengthening and digestion promoting；Celery seed puckery, the health care by these three materials separately as hypotensive is eaten
Product, one is that blood pressure lowering effect is not obvious, and two be that mouthfeel is bad, is unfavorable for oral.
The content of the invention
The technical problems to be solved by the invention be overcome prior art exist drawbacks described above there is provided a kind of hypotensive
Health composition.
Second object of the present invention is to provide the medicine containing above-mentioned health composition.
The purpose of the present invention is achieved by the following technical programs：
A kind of health composition of hypotensive, said composition is 50~70% mulberry leaf powders, 10~40% celery seeds and 4 by mass fraction
~20% hawthorn constitutes.
Although prior art has all been reported for mulberry leaf, hawthorn and celery seed for antihypertensive, it is single use
Each of which composition is not only bad to the effect of hypotensive, but also the symptoms such as mouthfeel discomfort occurs in the another eater of meeting,
We use high performance liquid chromatography in an experiment（HPLC）Detect to exist in celery seed extract solution and overlapped with GABA standard items
Peak, contain GABA in tentative confirmation celery seed.
Present invention research finds all to contain GABA in mulberry leaf, hawthorn and celery seed these three materials, and GABA is to hypotensive
Effectively, according to GABA content in three kinds of materials and the relation of the external inhibiting rate for suppressing ACE, three kinds of combinations of substances of optimization
Ratio, the portfolio ratio that three kinds of materials are optimized with the present invention is mixed, and can reach 100% to ACE inhibiting rate in vitro.
Preferably, mulberry leaf powder, celery seed and the mass ratio of hawthorn are 9~13 in said composition：3~9：1~3.
It is highly preferred that mulberry leaf powder, celery seed and the mass ratio of hawthorn are 9 in said composition：4：2.
Preferably, above-mentioned mulberry leaf powder is selected from ultramicro mulberry leaf powder；The celery seed is celery seed powder；The hawthorn is shone for chopping
Dry haw flakes wear into fine powder.
The present invention also provides the medicine containing the health composition.
Compared with prior art, the invention has the advantages that：
The invention provides a kind of health composition of hypotensive, said composition by mass fraction be 50~70% mulberry leaf powders, 10~
40% celery seed and 4~20% hawthorn composition；By the combination of these three materials, the deficiency of homogenous material presence can be eliminated, is subtracted
Few adverse reaction, such as hawthorn has neutralized the bitterness that is cold, alleviating celery seed of mulberry leaf, and hawthorn is sour sweet, and compatibility can be adjusted
Mouthfeel.Effect of mulberry leaf and celery seed causes blood pressure lowering effect more to protrude, and the blood pressure lowering effect after three kinds of material compatibilities
Blood pressure lowering effect than homogenous material is more preferable.
Brief description of the drawings
Fig. 1 is the recurrence line chart that Mori folium extract GABA concentration is made with ACE inhibiting rate relations.
Embodiment
Present disclosure is further illustrated below in conjunction with Figure of description and specific embodiment, but should not be construed as pair
The limitation of the present invention.In the case of spirit of the invention and essence, the modification made to the inventive method, step, condition
Or replace, belong to the scope of the present invention.Unless otherwise noted, experimental method used in embodiment is people in the art
Conventional method and technology known to member, reagent or material are to be obtained by commercial sources.
First, the preparation of raw material：
Growth selection is good, shine the quality plant material of agricultural chemicals without spray without insect pest, and removing moisture is dried or dried by the sun,
Again various material plant fine powders are obtained by mechanical crushing into fine powder.
2nd, the external hypotensive detection of various raw materials：
First by the method for low temperature water extraction, effective active composition therein is extracted from mulberry leaf, celery seed, hawthorn, by surveying
Extract solution is determined to angiotensin converting enzyme（Angiotensin converting enzyme, ACE）Inhibition sentenced
It is fixed.ACE participates in the regulation of blood pressure in human body by renin-angiotensin system and kallikrein kinin system：Pass through
ACE vasoactives Angiotensin Converting Enzyme I, His-Leu generation angiotensinⅡs are removed from its C-terminal, and angiotensinⅡ is acted on
Parteriole, makes vascular smooth muscle contraction, so as to cause elevation of the blood pressure.AngiotensinⅡ can be reduced by taking ACE inhibitor
Generation, reaches the purpose for the treatment of hypertension.The index of current vitro detection hypotensive is mainly inhibiting rate of the detection to ACE.
ACE inhibitory activity measure with reference to Nakamura and Cushman method and carried out as the case may be necessarily
Modification, specific method is as follows：
The μ L of aqueous extract 20 of plant fine powder are taken, make 50 mmol/L Hepes buffer solutions of substrate with HHL containing 5mmol/L（Contain
0.3mol/L NaCl, pH8.3）50 μ L are mixed, and 3min is preheated in 37 DEG C of water-baths, 10 μ L enzyme liquids are then added（0.1U/mL）.
Mixed liquor is reacted into 30min at 37 DEG C, 200 μ L 1mol/L hydrochloric acid terminating reactions are added.1.2 mL ethyl acetate are added, are shaken
15s, 4000r centrifugation 10min are swung, the mL ethyl acetate layers of upper strata 0.8 are separated.The layer is gone in 120 DEG C of heating volatilizations organic molten
Agent, adds 0.8 mL tri-distilled waters and vibrating is completely dissolved hippuric acid, it is determined in 228nm with micro ultraviolet specrophotometer
Light absorption value（Control group is that extract solution is replaced with into distilled water）.
ACE inhibitory activity is calculated by below equation：
ACEI(%)=（A-B）/A×100
In formula：A represents the light absorption value that hippuric acid is generated after ACE and HHL reactions completely.
B represents extract solution with generating the light absorption value of hippuric acid after ACE and HHL reactions.
（A-B）Represent makes the amount of hippuric acid reduction due to adding extract solution.
3rd, the technological process of tablet is made：
Each raw material are sufficiently stirred for mixing after mixing according to portfolio ratio preferably out, the auxiliary material that addition tabletting needs, mainly
There are glucose, malt saccharin, cornstarch, magnesium stearate（Food additives）.Outer packing is cleared up, ultraviolet disinfection is after one hour
Enter machined areas by transmitting window.
Technological process is as follows：
GABA is in its relation to ACE inhibiting rates in the mulberry leaf of embodiment 1, celery seed, hawthorn
The aqueous extract of mulberry leaf fine powder is obtained according to the method described above, and detects wherein GABA concentration, and with containing different GABA
The mulberry leaf fine powder aqueous extract of concentration detects its inhibiting rate to ACE, as a result such as table 1.
Regression equation is obtained according to table 1, equation is：Y=11.4x+79.76, wherein：X represents GABA concentration；Y represents ACE
Inhibiting rate.
By significance test, following result is drawn（Table 2）
As can be drawn from Table 2, regression equation y=11.4x+79.76, R2=0.8486, P<0.05 is the level of signifiance, explanation
Within the specific limits there is linear relationship in the ACE inhibiting rates of Mori folium extract with GABA concentration, can be asked by linear regression equation
Obtain the corresponding GABA concentration on some ACE inhibiting rates point.
By can be calculated：When ACE inhibiting rates are 100%, GABA concentration is 1.8mg/mL in mulberry leaf fine powder aqueous extract.
Likewise, according to GABA concentration in celery seed fine powder aqueous extract and the relation of ACE inhibiting rates, trying to achieve recurrence side
Cheng Wei：Y=38.53x+63.78, R2=0.9684, when can reach 100% in the hope of external ACE inhibiting rates, celery seed fine powder water extraction
The concentration for taking GABA in liquid is 0.77 mg/mL.
According to GABA concentration in hawthorn fine powder aqueous extract and the relation of ACE inhibiting rates, trying to achieve regression equation is： y=
374.78x+64.55, R2=0.9633, GABA concentration is 0.09 mg/mL in hawthorn fine powder aqueous extract.
The mulberry leaf of embodiment 2, celery seed, the determination of hawthorn three's optimum combination ratio
According to the regression equation set up in experiment of single factor, concentration of the inhibiting rate of every kind of material under 80%, 85%, 90% is chosen
It is 1 according to volume ratio：1：1 carries out orthogonal experiment, calculates GABA concentration as follows：
According to the regression equation of embodiment 1, three levels for drawing mulberry leaf powder factor are 1,2,3, and corresponding extract solution GABA is dense
Degree is divided into other 0.11 mg/mL, 0.47 mg/mL, 0.93 mg/mL.
Three levels of celery seed factor are 1,2,3, and corresponding extract solution GABA concentration is divided into other 0.16 mg/mL, 0.31
mg/mL、0.46 mg/mL。
Three levels of hawthorn factor are 1,2,3, and corresponding extract solution GABA concentration is divided into other 0.02 mg/mL, 0.04
mg/mL、0.06 mg/mL；Orthogonal experiments such as table 3.
Analysis show that in these three materials the inhibitory action on ACE enzymes influences size to be mulberry leaf powder ＞ hawthorn ＞ celeries
Seed.Select and excellent be combined as A3 B2 C3 .According to the content Conversion Calculation of GABA in each material, the formula of excellent combination is mulberry leaf（g）：
Celery（g）：Hawthorn（g）=9：4：2.
And it can analyze and draw from Orthogonal experiment results, in the case where volume is equal, the ACE of homogenous material suppresses
Rate is respectively 90%（Mulberry leaf powder）、80%（Celery seed）、90%（Hawthorn）, and by after three kinds of materials in equal volume mixing（The totality of detection
Product is constant）, ACE inhibiting rates have reached 100%, have illustrated that three kinds of mixed blood pressure lowering effects of material are better than the effect of homogenous material
Really.
Orthogonal test is verified again, tested number 7,8,9 and optimum combination, which are carried out external ACE, to be suppressed to detect, its
Middle tested number 7,8,9 is converted into the ratio such as table 4 of every kind of material.
Detect the result such as table 5.
Obtained by confirmatory experiment：More than in the mixed proportion of several materials, the external ACE suppressions of mixed proportion of optimum combination
Preferably, i.e., the mixed proportion of every kind of material is mulberry leaf to rate processed（g）：Celery（g）：Hawthorn（g）=9：4：When 2, external blood pressure lowering effect
It is best.
Calculated by the content of GABA in various materials with corresponding required concentration, in vitro inhibition identical situation
Under, the optimum combination ratio is compared with single material, and the consumption of raw material is only the 42% of 25% and pure celery seed of pure mulberry leaf powder,
I.e. on the premise of identical ACE inhibitions are reached, use of the consumption compared with single substance of the combination of three kinds of materials of the present invention
Amount is significantly reduced.
Claims (4)
1. a kind of health composition of hypotensive, it is characterised in that said composition is 50~70% mulberry leaf powders, 10 by mass fraction
~40% celery seed and 4~20% hawthorn composition.
2. the health composition of hypotensive according to claim 1, it is characterised in that mulberry leaf powder, celery in said composition
Seed and the mass ratio of hawthorn are 9~13：3~9：1~3.
3. the health composition of hypotensive according to claim 2, it is characterised in that mulberry leaf powder, celery in said composition
Seed and the mass ratio of hawthorn are 9：4：2.
4. the medicine containing any one of claims 1 to 3 health composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710170853.3A CN106962910B (en) | 2017-03-21 | 2017-03-21 | Health-care composition for reducing blood pressure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710170853.3A CN106962910B (en) | 2017-03-21 | 2017-03-21 | Health-care composition for reducing blood pressure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106962910A true CN106962910A (en) | 2017-07-21 |
| CN106962910B CN106962910B (en) | 2020-12-29 |
Family
ID=59328658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710170853.3A Active CN106962910B (en) | 2017-03-21 | 2017-03-21 | Health-care composition for reducing blood pressure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106962910B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109452519A (en) * | 2018-11-07 | 2019-03-12 | 美利新(天津)生物科技有限公司 | A kind of solid beverage for clearing up blood toxicity |
| CN109511984A (en) * | 2019-01-09 | 2019-03-26 | 丁强 | A kind of special dietary seafood with the alleviation gout that celery seed, potassium citrate etc. are primary raw material preparation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391834A (en) * | 2002-07-11 | 2003-01-22 | 谢春生 | Celery oral lozenge and its preparing method |
| CN1919027A (en) * | 2006-08-25 | 2007-02-28 | 华雪芳 | Healthy tea and its preparing method |
| CN104621296A (en) * | 2013-11-11 | 2015-05-20 | 南京拓鉒医药科技有限公司 | Blood lipid, glucose and pressure regulating traditional Chinese medicine combined tea drink |
| CN105362394A (en) * | 2014-09-02 | 2016-03-02 | 刘海燕 | Celery seed blood pressure and blood lipid reducing medicine and preparing method thereof |
| CN105557905A (en) * | 2015-11-08 | 2016-05-11 | 陕西理工学院 | Weight losing sandwiched biscuit and preparation method thereof |
-
2017
- 2017-03-21 CN CN201710170853.3A patent/CN106962910B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391834A (en) * | 2002-07-11 | 2003-01-22 | 谢春生 | Celery oral lozenge and its preparing method |
| CN1919027A (en) * | 2006-08-25 | 2007-02-28 | 华雪芳 | Healthy tea and its preparing method |
| CN104621296A (en) * | 2013-11-11 | 2015-05-20 | 南京拓鉒医药科技有限公司 | Blood lipid, glucose and pressure regulating traditional Chinese medicine combined tea drink |
| CN105362394A (en) * | 2014-09-02 | 2016-03-02 | 刘海燕 | Celery seed blood pressure and blood lipid reducing medicine and preparing method thereof |
| CN105557905A (en) * | 2015-11-08 | 2016-05-11 | 陕西理工学院 | Weight losing sandwiched biscuit and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 99健康网: "桑叶山楂茶的泡法", 《99健康网》 * |
| 百**********: "芹菜籽水和山楂水能同时喝吗", 《百度拇指医生》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109452519A (en) * | 2018-11-07 | 2019-03-12 | 美利新(天津)生物科技有限公司 | A kind of solid beverage for clearing up blood toxicity |
| CN109511984A (en) * | 2019-01-09 | 2019-03-26 | 丁强 | A kind of special dietary seafood with the alleviation gout that celery seed, potassium citrate etc. are primary raw material preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106962910B (en) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105753935B (en) | Small-molecule peptides of sunflower head as well as preparation method and medical application of small-molecule peptide | |
| CN102648751B (en) | Engineering rice with functions of alleviating hangover and protecting liver and preparation method of engineering rice | |
| CN101603010A (en) | A kind of fast cultivation method for Taisui | |
| CN102599589B (en) | Method for preparing Noni fruit juice by fermentation method | |
| CN109730180A (en) | A kind of lowering blood pressure and blood fat, hypoglycemic composition and preparation method thereof and tea bag | |
| CN102362627A (en) | Healthcare coffee containing cordyceps | |
| CN102008076A (en) | Egg albumen nutrition mixture beneficial to adjustment of immune function and preparation method thereof | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| CN106962910A (en) | A kind of health composition of hypotensive | |
| CN102177993B (en) | Stomach-strengthening and digestion-promoting tea and preparation method thereof | |
| CN102382751A (en) | Purple sweet potato burdock healthcare vinegar | |
| CN1230160C (en) | Application of bamboo leaf total flavone in medicine for treating and preventing prostata disease and health-care-food | |
| CN101380128A (en) | Zhukui multifunctional health care beverage and production method thereof | |
| CN105995271A (en) | Blood pressure lowering drink | |
| CN108294211A (en) | A kind of functional solid beverage and preparation method thereof containing glucorphanin | |
| US20100310688A1 (en) | acacia extracts and their compounds on inhibition of xanthine oxidase | |
| CN102379391A (en) | Preparation of health food of pine pollen, glucan and natto | |
| CN106880042A (en) | A kind of full nutrition formula food suitable for fat, fat reducing patient with operation convalescence | |
| CN101948473B (en) | New NEO-clerodane diterpenoid compound and application thereof | |
| CN103239470B (en) | Dual-mushroom polysaccharide composition containing coprinus comatus polysaccharide and lentinan as well as preparation method and application thereof | |
| CN102379416A (en) | Preparation of novel natto health food | |
| CN109820123A (en) | A kind of plant beverage and preparation method thereof improving microcirculation | |
| CN101427833A (en) | Process for preparing low-alcohol beverage of rice | |
| CN1060028C (en) | Health food macte from cereal, vegetable and fruit | |
| CN101077873B (en) | Novel NEO-clerodane type diterpene compound and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220621 Address after: No. 3510, 35 / F, building 1, No. 500, middle section of Tianfu Avenue, Chengdu hi tech Zone, China (Sichuan) pilot Free Trade Zone, Chengdu, Sichuan 610096 Patentee after: Sichuan qianyiding Technology Co.,Ltd. Address before: 510642 No. five, 483 mountain road, Guangzhou, Guangdong, Tianhe District Patentee before: SOUTH CHINA AGRICULTURAL University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220701 Address after: 430000 room C001, 4th floor (1-3), building 5, international enterprise center, No.1 Guanshan Second Road, Wuhan East Lake New Technology Development Zone, Wuhan, Hubei Province Patentee after: Wuhan mihuan Health Industry Development Co.,Ltd. Address before: No. 3510, 35 / F, building 1, No. 500, middle section of Tianfu Avenue, Chengdu hi tech Zone, China (Sichuan) pilot Free Trade Zone, Chengdu, Sichuan 610096 Patentee before: Sichuan qianyiding Technology Co.,Ltd. |